Parkinson’s disease directly affects the heart and cardiovascular system, not just through the movement symptoms people associate with it but through damage to the nerves that control heart function. The disease process strips away sympathetic nerve fibers from the heart itself, disrupts blood pressure regulation, and alters heart rhythm. These cardiovascular complications are common enough that researchers now consider them a core feature of Parkinson’s rather than a side note.
How Parkinson’s Damages the Heart’s Nerve Supply
The hallmark of Parkinson’s disease is the loss of dopamine-producing neurons in the brain, but that same destructive process extends well beyond the brain. In Parkinson’s, abnormal clumps of a protein called alpha-synuclein accumulate in nerve cells throughout the body, including the nerves that supply the heart. Animal research has shown that pathological alpha-synuclein spreads through autonomic ganglia to reach the heart, where it appears in myocardial nerve terminals and the nerve fibers surrounding cardiac blood vessels.1Nature Communications. Autonomic ganglionic injection of α-synuclein fibrils as a model of pure autonomic failure α-synucleinopathy The result is cardiac sympathetic denervation: the heart gradually loses its connection to the sympathetic nervous system, the branch of the nervous system responsible for speeding the heart up, increasing the force of its contractions, and helping regulate blood pressure.
Research has confirmed that many people with Parkinson’s show clear evidence of this cardiac nerve loss, with the most pronounced denervation found in those who also have blood pressure regulation problems.2PubMed. Cardiac sympathetic denervation in Parkinson disease A specialized imaging technique called MIBG scintigraphy, which measures how well the heart takes up a tracer that mimics the neurotransmitter norepinephrine, can detect this denervation. In Parkinson’s, tracer uptake is reduced, reflecting the loss of postganglionic sympathetic nerve endings in the heart muscle.3PubMed Central. Cardiac 123I-MIBG Scintigraphy in Neurodegenerative Parkinson Syndromes: Performance and Pitfalls in Clinical Practice This imaging finding is distinctive enough that clinicians sometimes use it to help distinguish Parkinson’s from other conditions that look similar, such as multiple system atrophy, where heart nerve supply tends to be preserved.4PubMed. Cardiac (123)I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease with and without autonomic failure
Blood Pressure That Swings in Both Directions
The most visible cardiovascular problem in Parkinson’s is orthostatic hypotension, a sharp drop in blood pressure when you stand up. In people with Parkinson’s, this drop happens because the damaged sympathetic nerves can no longer constrict blood vessels quickly enough to keep blood from pooling in the legs. The symptoms are more varied than people expect: lightheadedness and dizziness are the obvious ones, but orthostatic hypotension also causes unexplained falls, fainting, blurred vision, fatigue, shortness of breath, and even neck and shoulder pain that appears only when standing.5PubMed Central. Management of Orthostatic Hypotension in Parkinson’s Disease Some people experience cognitive fogginess on their feet that clears when they sit down, because the brain is not getting enough blood flow in the upright position.6PubMed. Neurogenic Orthostatic Hypotension: An Underrecognized Complication of Parkinson Disease
Left untreated, orthostatic hypotension limits independence by making everyday activities dangerous. A simple screening involves measuring blood pressure while lying down and again three minutes after standing up. If systolic pressure drops by 20 mmHg or more, or diastolic pressure drops by 10 mmHg or more, orthostatic hypotension is present. Further testing can distinguish the neurogenic form caused by nerve damage from other causes like dehydration or medication side effects.5PubMed Central. Management of Orthostatic Hypotension in Parkinson’s Disease
The tricky part is that many people with Parkinson’s also develop supine hypertension, meaning their blood pressure climbs too high when they lie down. One study of newly diagnosed Parkinson’s patients found that about 46% already had supine hypertension, defined as blood pressure at or above 140/90 mmHg while lying flat.7PubMed. Clinical characteristics of supine hypertension in de novo Parkinson disease Another study reported a rate of about 34% in a group of Parkinson’s patients and found that those with supine hypertension also tended to have larger blood pressure drops when standing, as well as more cardiovascular comorbidities overall.8PubMed. Supine hypertension in Parkinson’s disease and multiple system atrophy These two conditions, orthostatic hypotension and supine hypertension, are essentially opposite problems living in the same person. Treating one tends to worsen the other, which makes blood pressure management in Parkinson’s a genuine clinical puzzle.9PubMed. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets
Changes in Heart Rate and Rhythm
A healthy heart does not beat like a metronome. The interval between beats fluctuates constantly, driven by the push and pull of the sympathetic and parasympathetic nervous systems. This fluctuation, called heart rate variability, is actually a sign of a well-functioning cardiovascular system. In Parkinson’s, heart rate variability is reduced. People with the disease show lower variability in both the measures linked to parasympathetic activity and those reflecting overall autonomic balance compared to healthy controls.10npj Parkinson’s Disease. Heart-brain synchronization breakdown in Parkinson’s disease This reduction can appear very early. One study found that decreased heart rate variability during sympathetic-dominant states was already present in people with isolated REM sleep behavior disorder, a condition that often precedes Parkinson’s by years, and in Parkinson’s patients at the mildest clinical stage.11PubMed. Decreased heart rate variability in sympathetic dominant states in Parkinson’s disease and isolated REM sleep behavior disorder
A large community-based study went further, following thousands of initially healthy adults over time and finding that those with the lowest heart rate variability at baseline had roughly two to three times the risk of later developing Parkinson’s disease compared to those with the highest variability.12PubMed Central. Heart rate variability and the risk of Parkinson’s disease: the Atherosclerosis Risk in Communities (ARIC) Study That finding raises an interesting possibility: changes in the heart’s autonomic regulation may be among the earliest detectable signs of the disease, appearing before the tremor and slowness that lead to diagnosis.
QT Prolongation and Arrhythmia Risk
Beyond heart rate variability, the electrical activity of the heart itself is altered in Parkinson’s. A systematic review found that the QT interval, the time it takes the heart to electrically reset between beats, is significantly longer in Parkinson’s patients than in controls by about 11 milliseconds on average. People with Parkinson’s had roughly 2.6 times the odds of having a prolonged corrected QT interval.13PubMed Central. The QT interval in Parkinson’s disease: a systematic review A prolonged QT interval matters because it increases the window in which the heart is vulnerable to dangerous rhythm disturbances.
Some of this prolongation comes from the disease itself, and some comes from the medications used to treat it. A screening study of Parkinson’s patients found that QT prolongation was significantly linked to both the stage of the disease and the use of medications known to lengthen the QT interval.14Parkinsonism & Related Disorders. Outcomes of screening Parkinson’s patients for QTc prolongation An additional study confirmed that both QT duration and broader measures of cardiac electrophysiological balance were altered in Parkinson’s patients compared to controls.15PubMed Central. Index of cardio-electrophysiological balance and Parkinson disease This matters practically because many people with Parkinson’s take multiple medications, and some common drugs for unrelated conditions (certain antibiotics, antidepressants, anti-nausea drugs) also lengthen the QT interval. The combination can push risk higher.
Heart Failure and Coronary Artery Disease
The relationship between Parkinson’s and more traditional forms of heart disease has been harder to pin down, but recent population-level research paints a concerning picture. A large nationwide longitudinal study from Korea found that people with Parkinson’s had more than five times the rate of developing congestive heart failure compared to matched controls, a difference that held across subgroups defined by age, sex, and other conditions like diabetes and hypertension.16PubMed Central. The Association between Parkinson’s Disease and Congestive Heart Failure in Korea: A Nationwide Longitudinal Cohort Study The mechanisms behind this are not fully understood, but structural cardiac changes have been reported in Parkinson’s patients, including left ventricular hypertrophy (thickening of the heart’s main pumping chamber) and diastolic dysfunction (stiffening that impairs the heart’s ability to relax and fill).17PubMed. Parkinson’s disease & cardiovascular disease: A narrative review Whether these changes stem from the loss of sympathetic nerve supply, from chronic blood pressure dysregulation, or from other shared biological pathways remains an open question.
A meta-analysis examining the link between Parkinson’s and coronary artery disease found a statistically significant association in cohort studies, with people who had Parkinson’s showing roughly double the risk of coronary disease after sensitivity analysis.18PubMed Central. Association Between Parkinson’s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis Case-control studies showed a similar trend that did not quite reach statistical significance. This association is somewhat surprising, because Parkinson’s patients tend to have lower rates of smoking, a major risk factor for heart disease. The elevated coronary risk despite that protective factor suggests something intrinsic to the disease process, or its treatment, is involved. The evidence on ischemic heart disease, heart failure, and arrhythmias has grown enough that researchers increasingly recognize Parkinson’s as a condition with meaningful cardiovascular consequences, even if the underlying mechanisms are not entirely clear.19PubMed Central. Parkinson’s disease and cardiovascular involvement: Edifying insights
How Parkinson’s Medications Affect the Heart
Some cardiovascular problems in Parkinson’s are not caused by the disease itself but by its treatment. Levodopa, the most effective and widely used Parkinson’s medication, can lower blood pressure. A study of older patients at early-to-middle stages found that higher doses of levodopa caused significant blood pressure drops in both lying and standing positions, with roughly 23% of patients developing orthostatic hypotension when tested off their medication and about 30% when tested in their best medicated state.20PubMed Central. Effects of different levodopa doses on blood pressure in older patients with early and middle stages of Parkinson’s disease That said, the relationship is nuanced. A separate study found that while anti-Parkinson’s drugs taken at home did reduce blood pressure, acutely increasing the levodopa dose on top of that did not make the drop worse.21PubMed Central. Effect of Acute Levodopa Up-Titration on Blood Pressure in Patients With Early Stage Parkinson’s Disease: Results of a Levodopa Challenge Test For patients and doctors, the practical message is that blood pressure should be monitored regularly, especially when starting or adjusting Parkinson’s medications, but the fear of levodopa causing ever-worsening blood pressure drops may be overstated.
A more dramatic cardiac effect comes from a specific class of older Parkinson’s drugs called ergot-derived dopamine agonists, particularly pergolide and cabergoline. These drugs act on serotonin receptors in the heart valves, stimulating the growth of fibrous tissue on the valve leaflets. A landmark study found that clinically important valve regurgitation (moderate to severe leaking) occurred in about 23% of patients taking pergolide and about 29% of those on cabergoline, compared to roughly 6% of controls. Patients on non-ergot dopamine agonists showed no excess valve disease at all.22PubMed. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease The mechanism involves off-target activation of serotonin 2B receptors on heart valves.23PubMed. Dopamine agonists and valvular heart disease Pergolide has since been withdrawn from the U.S. market, and cabergoline is used at much lower doses for other indications (like prolactinoma treatment) where the valve risk is smaller. The non-ergot dopamine agonists now used for Parkinson’s, such as pramipexole and ropinirole, do not carry this valve risk. Some evidence suggests that valve changes can partially reverse after stopping the ergot-derived drugs.24PubMed. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists
Exercise Tolerance and the Heart’s Blunted Response
People with Parkinson’s often report that exercise feels harder than it should, and the cardiovascular system is part of the reason. A phenomenon called chronotropic incompetence, where the heart cannot speed up adequately during physical activity, has been documented in people with early Parkinson’s. Those with chronotropic incompetence achieved significantly lower peak oxygen uptake during exercise testing compared to Parkinson’s patients whose heart rate responded normally.25PubMed Central. Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson’s Disease A sluggish heart rate response during exercise means muscles receive less oxygen at the onset of activity, forcing the body to rely more on anaerobic metabolism, which leads to faster fatigue and reduced exercise capacity.26Physiology. Heart Rate and VO2 Kinetics in Patients with Parkinson’s Disease and Orthostatic Hypotension
This is particularly relevant because exercise is one of the few interventions consistently shown to slow the progression of Parkinson’s symptoms. If the heart cannot respond normally to physical demand, people may hit a ceiling of fatigue before they reach the exercise intensity that would benefit their brain. Recognizing chronotropic incompetence can help clinicians tailor exercise programs, adjusting expectations around target heart rates and incorporating more gradual warm-ups to accommodate the delayed cardiovascular response.
Cardiac Changes Before Diagnosis
One of the more striking findings in recent Parkinson’s research is that heart involvement does not wait for motor symptoms to appear. A case report documented profoundly decreased cardiac sympathetic nerve activity, measured with specialized imaging, a full four years before a patient developed the movement problems that led to a Parkinson’s diagnosis.27PubMed Central. Cardiac sympathetic denervation preceding motor signs in Parkinson disease Broader studies using MIBG scintigraphy have confirmed that reduced cardiac tracer uptake can appear even in the earliest clinical stages and in patients whose blood pressure responses still look normal on standard testing.28PubMed. Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled MIBG This has reinforced the idea that cardiac sympathetic denervation occurs early in the disease process, possibly among the first organs affected.29PubMed. Cardiac denervation and dysautonomia in Parkinson’s disease: a review of screening techniques
This timeline fits with the broader understanding that Parkinson’s disease involves a long “prodromal” phase during which the brain and body are already changing but the classic motor symptoms have not yet appeared. Sleep disturbances, loss of smell, constipation, and now cardiac autonomic dysfunction all belong to this prodromal window. The heart rate variability findings from the ARIC study, mentioned earlier, align with this picture: reduced variability in the general population predicted who would go on to develop Parkinson’s years later.12PubMed Central. Heart rate variability and the risk of Parkinson’s disease: the Atherosclerosis Risk in Communities (ARIC) Study None of these cardiac markers are specific enough to diagnose Parkinson’s on their own, but they add valuable pieces to the puzzle, and they underscore that the heart is involved from near the beginning.
Sudden Unexpected Death in Parkinson’s
A small but important body of research has drawn attention to the phenomenon of sudden and unexpected death in Parkinson’s disease, sometimes abbreviated SUDPAR. Compared to the general population, people with Parkinson’s carry higher rates of premature death, usually attributed to pneumonia or cerebrovascular and cardiovascular disease. But a meaningful fraction die suddenly without a clear preceding illness.30PubMed Central. Sudden unexpected death in Parkinson’s disease: Insights from clinical practice The exact mechanisms are still being investigated, but the cardiac electrical changes described above, particularly QT prolongation and reduced heart rate variability, are plausible contributors. Cardiac arrhythmias are a leading cause of sudden death in the general population, and Parkinson’s patients arrive at that risk with already-compromised cardiac autonomic function.
Managing Cardiovascular Complications
For orthostatic hypotension that significantly affects daily life, droxidopa is an FDA-approved treatment specifically for neurogenic orthostatic hypotension. It works by being converted into norepinephrine in the body, partially compensating for the neurotransmitter the denervated nerves can no longer supply. In patients who also have other cardiac conditions, including atrial fibrillation and heart failure, droxidopa has been shown to improve the ability to stand without worsening those existing heart problems.31PubMed Central. Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson’s Disease Non-drug measures also play a significant role: drinking extra fluids, increasing salt intake when appropriate, wearing compression garments, and sleeping with the head of the bed elevated can all help. The head-of-bed elevation trick is particularly useful for people who have both orthostatic hypotension and supine hypertension, because even a slight incline reduces nighttime blood pressure without worsening standing blood pressure the next morning.
Regular cardiovascular monitoring deserves more emphasis in Parkinson’s care than it typically receives. Blood pressure should be checked in both lying and standing positions, not just seated. An electrocardiogram can screen for QT prolongation, especially before starting new medications. And if someone with Parkinson’s reports unexplained fatigue during exercise, a blunted heart rate response should be on the differential, not just deconditioning. The cardiovascular side of Parkinson’s is often managed reactively, after a fall or a fainting episode. A more proactive approach, built on the understanding that nerve damage to the heart is an intrinsic part of this disease, would catch many of these problems earlier.